MX2020013155A - Composiciones y metodos para tratar la pancreatitis. - Google Patents
Composiciones y metodos para tratar la pancreatitis.Info
- Publication number
- MX2020013155A MX2020013155A MX2020013155A MX2020013155A MX2020013155A MX 2020013155 A MX2020013155 A MX 2020013155A MX 2020013155 A MX2020013155 A MX 2020013155A MX 2020013155 A MX2020013155 A MX 2020013155A MX 2020013155 A MX2020013155 A MX 2020013155A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- methods
- pcsk9
- compositions
- pancreatitis
- Prior art date
Links
- 206010033645 Pancreatitis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 101710172072 Kexin Proteins 0.000 abstract 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 abstract 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/11—Aminopeptidases (3.4.11)
- C12Y304/11001—Leucyl aminopeptidase (3.4.11.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680896P | 2018-06-05 | 2018-06-05 | |
| PCT/US2019/035310 WO2019236528A1 (en) | 2018-06-05 | 2019-06-04 | Compositions and methods for treating pancreatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013155A true MX2020013155A (es) | 2021-04-29 |
Family
ID=68770590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013155A MX2020013155A (es) | 2018-06-05 | 2019-06-04 | Composiciones y metodos para tratar la pancreatitis. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11679146B2 (https=) |
| EP (1) | EP3801620A4 (https=) |
| JP (1) | JP2021532167A (https=) |
| CN (1) | CN112512574A (https=) |
| AU (1) | AU2019282132A1 (https=) |
| CA (1) | CA3102032A1 (https=) |
| MX (1) | MX2020013155A (https=) |
| TW (1) | TW202015727A (https=) |
| WO (1) | WO2019236528A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
| WO2022002160A1 (zh) * | 2020-07-01 | 2022-01-06 | 陈敏 | Pcsk9抑制剂在制备治疗多种疾病产品中的应用 |
| CN114250194B (zh) * | 2021-11-30 | 2023-04-11 | 四川大学华西医院 | 一种急性胰腺炎细胞模型的构建方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856487A (en) | 1996-02-14 | 1999-01-05 | National Institute Of Immunology | Application of protoberberine alkaloid, berberine, an immunosuppressive agent |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| CN101467999A (zh) | 2007-12-25 | 2009-07-01 | 郑州后羿制药有限公司 | 一种盐酸小檗碱复方制剂 |
| CN102088993A (zh) * | 2008-03-20 | 2011-06-08 | 卡罗勒斯治疗公司 | 炎症的治疗方法 |
| CN101829113B (zh) | 2009-07-14 | 2012-12-12 | 武汉大学 | 黄连素在治疗或预防流感病毒药物中的应用 |
| AU2010298249A1 (en) | 2009-09-23 | 2012-04-19 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| EP2849788B1 (en) * | 2012-05-17 | 2018-01-03 | Cyon Therapeutics Inc. | Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock |
| CN104815316A (zh) | 2015-05-25 | 2015-08-05 | 苗怡文 | 一种治疗急慢性胰腺炎的中药制剂及其制备方法 |
| US20190365656A1 (en) | 2016-01-04 | 2019-12-05 | Cour Pharmaceuticals Development Company, Inc. | Particles encapsulating fusion proteins containing linked epitopes |
| AU2017292184A1 (en) | 2016-07-08 | 2019-02-07 | Staten Biotechnology B.V. | Anti-Apoc3 antibodies and methods of use thereof |
| CN107468687A (zh) | 2017-09-05 | 2017-12-15 | 吴蕾 | 黄连素作为细胞m3受体抑制剂的用途 |
| US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
-
2019
- 2019-06-04 US US15/734,461 patent/US11679146B2/en active Active
- 2019-06-04 CN CN201980037654.2A patent/CN112512574A/zh active Pending
- 2019-06-04 WO PCT/US2019/035310 patent/WO2019236528A1/en not_active Ceased
- 2019-06-04 MX MX2020013155A patent/MX2020013155A/es unknown
- 2019-06-04 EP EP19815628.3A patent/EP3801620A4/en not_active Withdrawn
- 2019-06-04 CA CA3102032A patent/CA3102032A1/en active Pending
- 2019-06-04 AU AU2019282132A patent/AU2019282132A1/en not_active Abandoned
- 2019-06-04 JP JP2021518029A patent/JP2021532167A/ja active Pending
- 2019-06-05 TW TW108119591A patent/TW202015727A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11679146B2 (en) | 2023-06-20 |
| US20210213111A1 (en) | 2021-07-15 |
| EP3801620A1 (en) | 2021-04-14 |
| CA3102032A1 (en) | 2019-12-12 |
| JP2021532167A (ja) | 2021-11-25 |
| AU2019282132A8 (en) | 2023-05-25 |
| CN112512574A (zh) | 2021-03-16 |
| WO2019236528A1 (en) | 2019-12-12 |
| EP3801620A4 (en) | 2022-04-20 |
| TW202015727A (zh) | 2020-05-01 |
| AU2019282132A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013155A (es) | Composiciones y metodos para tratar la pancreatitis. | |
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| CR20220642A (es) | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 | |
| PH12021552497A1 (en) | Enzyme inhibitors | |
| NZ763161A (en) | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| ZA202407503B (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
| PL1660507T5 (pl) | Inhibitory proteazomu oraz sposoby ich stosowania | |
| MX2023002323A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| MY196729A (en) | Novel compounds | |
| MX2017003624A (es) | Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas. | |
| MY188957A (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| EA201690745A1 (ru) | Способы лечения и предотвращения болезни "трансплантат против хозяина" | |
| MX2016010011A (es) | Metodos para tratar y prevenir trastornos renales y trastornos del higado graso. | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| PH12021551070A1 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
| PH12021552588A1 (en) | Cd73 inhibitors | |
| MX2009000359A (es) | Metodos paratratar y limitar trastornos fibroticos y queloides. | |
| MX2022007113A (es) | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| MY162518A (en) | Proteasome inhibitors and methods of using the same | |
| MX2021000404A (es) | Oligonucleotidos para modular la expresion de rtel1. | |
| WO2019173478A3 (en) | Combination of depletes tregs and a checkpoint inhibitor | |
| WO2019115493A3 (en) | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |